Literature DB >> 15298235

The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example.

Joseph A Franciosa1.   

Abstract

BACKGROUND: Clinical trials do not represent community settings, making widespread implementation of evidence-based medicine problematic. New heart failure treatments are an example, as results comparable to those of clinical trials have not been observed in the community. Alternatives to clinical trials could provide useful complementary information. OBJECTIVES AND METHODS: To review the clinical trials and community experiences in heart failure management by searching Pubmed with key words "observational studies," "clinical trials," and "heart failure," to present the preliminary results of a community-based heart failure registry as a complementary database, and to assess the potential value and limitations of the registry approach.
RESULTS: Recent advances in the treatment of heart failure led to guidelines using clinical trial evidence as the rationale for transferring newer therapeutic technologies to the community practice setting. Implementation of such guidelines is slow, reflecting concerns over applicability of clinical trial results to the community setting. A community-based registry of beta-blocker treatment for heart failure showed outcomes comparable to those of clinical trials, despite significant differences between physicians and their patients in these settings.
CONCLUSION: Registries can complement clinical trials to expedite technology transfer to the community setting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298235

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

1.  Missed opportunities for the secondary prevention of cardiovascular disease in Canada.

Authors:  Daniel G Hackam; Lawrence A Leiter; Andrew T Yan; Raymond T Yan; Aurora Mendelsohn; Mary Tan; Louis Zavodni; Richard Chen; Jennifer L Tsang; Anjali Kundi; Peter J Lin; David H Fitchett; Anatoly Langer; Shaun G Goodman
Journal:  Can J Cardiol       Date:  2007-12       Impact factor: 5.223

2.  Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients.

Authors:  Kay Larholt; Chris L Pashos; Qin Wang; Brahim Bookhart; R Scott McKenzie; Catherine Tak Piech
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 3.  Similarities and differences in patient characteristics between heart failure registries versus clinical trials.

Authors:  Abhinav Sharma; Justin A Ezekowitz
Journal:  Curr Heart Fail Rep       Date:  2013-12

4.  Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients.

Authors:  Lesley H Curtis; Melissa A Greiner; Bradley G Hammill; Lisa D DiMartino; Alisa M Shea; Adrian F Hernandez; Gregg C Fonarow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-06-09

5.  Inhaled anticholinergic use and all-cause mortality among elderly Medicare beneficiaries with chronic obstructive pulmonary disease.

Authors:  Mayank Ajmera; Chan Shen; Xiaoyun Pan; Patricia A Findley; George Rust; Usha Sambamoorthi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-06-10

6.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.

Authors:  Tessa Kennedy-Martin; Sarah Curtis; Douglas Faries; Susan Robinson; Joseph Johnston
Journal:  Trials       Date:  2015-11-03       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.